Speaker Biographies

Mary R. Grealy, JD
President
Healthcare Leadership Council

Mary Grealy is president of the Healthcare Leadership Council, a coalition of chief executives of the nation’s leading healthcare companies and organizations. The HLC advocates consumer-centered health care reform, emphasizing the value of private sector innovation. It is the only health policy advocacy group that represents all sectors of the health care industry. She was appointed to the position in August 1999.

Ms. Grealy has an extensive background in healthcare policy. She has led important initiatives on the uninsured, improving patient safety and quality, protecting the privacy of patient medical information and reforming the medical liability laws. From 1995 until she began her tenure at HLC, she served as Chief Washington Counsel for the American Hospital Association. From 1979 to 1995, Ms. Grealy was Chief Operating Officer and Executive Counsel for the Federation of American Hospitals.

Ms. Grealy has a bachelor degree from Michigan State University and a law degree from Duquesne University. She is a member of the Board of Directors of TeamHealth, one of the largest providers of outsourced physician staffing solutions for hospitals in the United States, and the Board of Directors of Duquesne University serving on the Executive Committee. She is a member of the American Health Lawyers Association. She also serves on the advisory boards of Duke University Health Sector Advisory Council, Women Business Leaders in Health, the March of Dimes Public Policy Council and the Annapolis Wellness House. She is a frequent public speaker on health issues and has been ranked many times by Modern Healthcare as one of the 100 Most Powerful People in Healthcare and has been named to Modern Healthcare’s list of the Top 25 Women in Healthcare for 2009.

David Caraway, MD, PhD
CEO
The Center for Pain Relief Tri-State
St. Mary’s Regional Medical Center
Huntington, WV

Dr. Caraway is the CEO of The Center for Pain Relief, Tri-State, L.L.C. in partnership with St. Mary’s Regional Medical Center in Huntington, West Virginia to deliver state-of-the-art health care. Although the clinic provides comprehensive, multidisciplinary services, the emphasis of the practice is interventional pain management.

He is also the founder of David Caraway, MD, PhD, PLLC, located in Charlottesville, Virginia. This firm provides consulting, lecturing, medical-legal review and compliance planning with the mission of elevating the field of pain management through education,
research, development and deployment of new therapies while promoting “best practice” strategies. The corporation has provided consultation services to medical societies, worker’s compensation carriers, private practitioners, hospitals, legal firms, regulatory offices, insurance companies, medical device manufacturers and the pharmaceutical industry.

Dr. Caraway is a graduate of the University of Virginia School of Medicine where he received his MD and of the University of Virginia Graduate School of Arts and Sciences receiving a PhD in Biophysics. He also holds a BS in Chemical Engineering from the University of Virginia School of Engineering. He received post-graduate training in anesthesiology and pain management from the University of Virginia.

Dr. Caraway is board certified by the American Board of Anesthesiology. Dr. Caraway serves as the Executive Vice President of Strategic Planning and Board of Directors member for the American Society of Interventional Pain Physicians and is member of the Board of Directors of the North American Neuromodulation Society. He is a member of and frequent lecturer at the national meetings of the American Society of Anesthesiologists and the American Academy of Pain Medicine. Dr. Caraway serves as an advisor to the Neuromodulation Therapy Access Coalition and various patient advocacy groups.

Dr. Caraway is nationally recognized as an expert in the treatment of chronic pain. He lectures regionally, nationally and internationally in the field of Interventional Pain Medicine. He has authored and contributed to numerous publications in this field including recently published guidelines for the appropriate use of implantable therapies.

Guy Chisolm, MD, PhD
Director, Innovation Management & Conflict of Interest Program
Cleveland Clinic

Dr. Chisolm is currently Vice Chairman of the Lerner Research Institute of Cleveland Clinic, where he is a Professor of Cell Biology. He also holds active secondary professorships in the Cleveland Clinic Lerner College of Medicine (CCLCM) of Case Western Reserve University, Kent State University and Cleveland State University. He is also Director of Cleveland Clinic’s Innovation Management and Conflict of Interest Program.

He received a BS from the University of Pennsylvania (Philadelphia), PhD from the University of Virginia (Charlottesville) and postdoctoral research training from the Karolinska Institute (Stockholm) and Massachusetts Institute of Technology (Cambridge).

Dr. Chisolm has published over 110 scientific articles, most on vascular biology and the cell biology of atherosclerosis. His work and contemporaneous studies from others led to the theory that oxidation of low density lipoprotein, LDL, accelerates atherosclerosis.
His laboratory continues to study oxidized LDL's influence on gene expression, programmed cell death, cell proliferation, pro-coagulation processes and "foam cell" formation. His research funding has come predominantly from multiple grants from the NIH, the American Heart Association and the pharmaceutical industry. Dr. Chisolm received the Research Merit Award from the American Heart Association's Ohio Valley Affiliate (2001) and a Special Recognition Award for Vascular Biology Research from the AHA's (national) Council on Arteriosclerosis, Thrombosis and Vascular Biology (2006).

**Cleveland Clinic (institutional leadership, service, education):** Dr. Chisolm has served on Cleveland Clinic's Board of Governors and Board of Trustees. He is actively involved in numerous aspects of Cleveland Clinic's new medical school, the CCLCM. He is co-director of the school's Basic Science Curriculum and sits on the Admissions, Faculty Appointments and Promotions, Student Promotion and GI Curriculum committees. He is recipient of the 2007 Lerner Research Institute Award for Excellence in Education.

**Conflict of Interest:** Dr. Chisolm is Director of Cleveland Clinic's Innovation Management and Conflict of Interest Program, Chairman of the IM&Col Committee and a member of the Clinic's Board of Trustees Col Committee. He played an active role in crafting the Clinic's current Col policies. He is on the Steering Committee for the Association of American Medical College Forum on Conflict of Interest in Academe and in 2006 hosted at Cleveland Clinic the annual national meeting of this organization and another national summit on Col (9/06). He has been on the program planning committees for the Forum’s national meetings sponsored by Johns Hopkins University School of Medicine (9/07) and Mayo Clinic (9/08). He was a member of the joint AAMC-AAU Advisory Committee on Conflicts of Interest in Human Subjects Research that recently published updated Col guidelines. He is a member of CWRU’s Col Committee and CWRU’s President’s Committee on Col Policy Development.

**American Heart Association:** Dr. Chisolm has served the AHA at the regional and national level in numerous committees, task forces and as an officer. He has, for example, served as a member of the Board of Trustees and Board of Directors of regional affiliates, as the President of the regional affiliate, on multiple research peer-review study sections, including as chairman, at the regional and national level. He is an active member and recent officer of the AHA’s Council on Arteriosclerosis, Thrombosis and Vascular Biology.

**NIH and Other National Committees:** He has served on multiple NIH committees, including the NHLBI Study Section for Program Projects (Chair), the Metabolism Study Section, and the Data Management and Safety Board for the "Arterial Disease Multiple Intervention Trial". He is a member of multiple professional societies.

**Editorial Boards and manuscript review:** Dr. Chisolm has served as Associate Editor or on the Editorial Board of American Journal of Physiology: Heart and Circulatory
Physiology, Arteriosclerosis, Thrombosis and Vascular Biology, and Journal of Biological Chemistry. He has been an ad hoc reviewer for over forty scientific journals.

**Industry Relationships:** Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/17/2012, Dr. Chisolm has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our [Integrity in Innovation](#) page.

**Public Health Service-Reportable Financial Conflicts of Interest.** Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
Ryan Hohman JD, MPA, serves as Managing Director, Policy & Public Affairs of Friends of Cancer Research (Friends), a cancer research think tank and advocacy organization based in the Washington, D.C. area. Working with the entire cancer research and advocacy community, Friends pioneers innovative public-private partnerships, organizes critical policy forums, educates the public, and brings together key stakeholders to overcome the barriers standing between patients and the most promising cancer treatments.

Before joining Friends, Mr. Hohman was Director of Corporate and Institutional Partnerships at Georgetown University's Lombardi Comprehensive Cancer Center. While at Georgetown, Ryan focused on the development and execution of strategic corporate and philanthropic engagement to support the center’s biomedical research and cancer treatment.